IMpassion050: A phase 3 study of neoadjuvant atezolizumab + pertuzumab + trastuzumab + chemotherapy in high-risk, HER2-positive early breast cancer

The ESMO Virtual Plenaries are freely available to all healthcare professionals working in Oncology.

Programme

Thursday, 17 June 2021

19:30-20:30 CEST

Welcome and introduction, Scientific background and context

Nadia Harbeck, LMU Klinikum der Universität München, Munich, Germany

IMpassion050: A phase 3 study of neoadjuvant atezolizumab + pertuzumab + trastuzumab + chemotherapy in high-risk, HER2-positive early breast cancer

Jens Huober, Cantonal Hospital, Breast Center St. Gallen, St. Gallen, Switzerland 

Critical analysis and perspectives

Evandro de Azambuja, Institute Jules Bordet, Brussels, Belgium

Discussion and Q&A (i)

Faculty and online audience

Friday, 18 June 2021

13:15-14:15 CEST (19:15 HKT / 20:15 JST / 21:15 AEST)

Webcast of 17 June presentations, Discussion and Q&A (ii)

Faculty and online audience:

Chair: Yeon Hee Park, Samsung Medical Center (SMC) - Sungkyunkwan University School of Medicine, Seoul, Republic of Korea

Jens Huober, Cantonal Hospital, Breast Center St. Gallen, St. Gallen, Switzerland

Evandro de Azambuja, Institute Jules Bordet, Brussels, Belgium

Sherene Loi, Peter MacCallum Cancer Centre, Melbourne, Australia

Shigehira Saji, Saitama, Fukushima Medical University, Fukushima, Japan